Support MI up for updates Subscribe up for updates
About Research Events Centers Newsroom Currency of Ideas
 
Milken Institute | Research | Publications | Research Reports: The Global Biomedical Industry: Preserving U.S. Leadership
 The Global Biomedical Industry: Preserving U.S. Leadership
The Global Biomedical Industry: Preserving U.S. Leadership
September 22, 2011
Biomedical | Business | Emerging Markets | Health | Job Creation | Leadership | Public Policy | Science | Technology | U.S. Economy
Publisher: Milken Institute

Buy Printed Version $ 20.00

Click here for the Executive Summary.

The United States is still the global leader in the biomedical industry, but countries across Europe and Asia are pursuing aggressive plans to close the gap and take the high-value jobs and capital this sector creates.

The stakes are high: The biomedical sector directly and indirectly accounts for some 5 million U.S. jobs (including 1.2 million high-wage private-sector jobs in pharmaceuticals, biotech, medical devices, research and testing).

Multiple factors leave the U.S. vulnerable to growing international competition: increasing complexity and uncertainty in the FDA's approval processes, especially as these relate to medical devices; government funding cuts; and federal tax policies that are not globally competitive.

European and Asian nations are investing heavily in research as well as improving access to capital for biotech start-ups. They are also taking a page from the U.S. playbook as they standardize their regulatory regimes and offer better incentives for innovation.

Beyond the established biopharmaceutical leaders in Europe and Japan, China, India and Singapore are making impressive strides in building their capacity for research, clinical testing and manufacturing. The world's best scientific talent traditionally flocked to the U.S., but today these highly prized knowledge workers are finding new job opportunities at home.

U.S. policymakers must take these seven decisive steps for the nation to retain its lead in biomedical innovation:

  • Increase R&D tax incentives and make them permanent
  • Cut corporate tax rates to match the OECD average
  • Enhance support for emerging fields
  • Provide adequate resources for the FDA and the NIH
  • Leverage existing strengths in medical devices
  • Build human capital
  • Promote and expand the role of universities

"The Global Biomedical Industry: Preserving U.S. Leadership" was funded in part by a grant from the Council for American Medical Innovation. The views expressed in the report are solely those of the Milken Institute.

 
Search All Publications
Paper or pixels?
2 ways to subscribe to
the Milken Institute Review
Download the app for
iPhone, iPad and Kindle

Buy new digital editions of our quarterly economics journal for $1.99, purchase back issues for 99 cents or get a year's subscription for $5.99. Access links to related video and other content.
Order a 1-year subscription
Receive hard copies for $59, a small price to pay for our edgy, accessible and expert take on the latest in economics.
Subscribe Now
About Us
  Careers
  Contact
  Download Annual Report
  FAQs
  Locations
  Our Team

Blog


Topics

Events
  Associates
  Conferences
  Global Conference
  Partnering for Cures
  State of the State
  Summits
  Asia / California / London
  Forums
  Labs
  Young Leaders

Experts
Newsroom
  Latest News
  News Videos
  Press Releases

Research
  Centers
    Asia
    California
    FasterCures
    Financial Markets
    Jobs and Human Capital
    Public Health

Initiatives

Publications
  Books
  Financial Innovations Labs
  Milken Institute Review
   Amazon Apps
   App Store
  Research Reports
  Viewpoints
  Search All Publications
Support MI
  Associates
  Donate
  Sponsorships
  Strategic Partners

Follow Us
  @Twitter
  Facebook
  YouTube
  Google+
  LinkedIn
  iTunes U

Related Sites
  Partnering For Cures
  Celebration of Science
  Chairman's Corner
  Melanoma Research Alliance
  FasterCures

©2014 Milken Institute